AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31287135 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to imaging radiation during pregnancy
Number of subjects: 38
Study 31287135 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of moderate to high grade fever during pregnancy
Number of subjects: 38
Study 31287135 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid intake before and during pregnancy
Number of subjects: 38
Study 31287135 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of spina bifida
Number of subjects: 38
Study 29171489 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin with glucosamine hydrochloride and chondroitin sulfate
Number of subjects: 178
Study 29171489 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin with glucosamine hydrochloride, chondroitin sulfate, and diclofenac
Number of subjects: 178
Study 29171489 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin with diclofenac
Number of subjects: 178
Study 26011193 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic radiation force impulse (ARFI) imaging
Number of subjects: 30
Study 26011193 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal findings)
Number of subjects: 30
Study 26011193 — intervention group
Group type: EXPERIMENTAL
Intervention: ARFI imaging
Number of subjects: 30
Study 24552970 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive iPad-based informational program (IPI)
Number of subjects: 151
Study 24552970 — intervention group
Group type: COMPARATOR
Intervention: Standard institutional verbal and written information (SI)
Number of subjects: 151
Study 22084157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lensectomy and anterior vitrectomy
Number of subjects: 114
Study 22084157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens implant
Number of subjects: 114
Study 22084157 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treated eye
Number of subjects: 114
Study 20351873 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive self-care framework
Number of subjects: 0
Study 17466473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (4 sessions of instructions on preterm infant behavior for 2 weeks)
Number of subjects: 22
Study 17466473 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instructions)
Number of subjects: 22
Study 15892277 — intervention group
Group type: EXPERIMENTAL
Intervention: Activating blood circulation to remove blood stasis recipe (ARR)
Number of subjects: 60
Study 15892277 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine
Number of subjects: 60
Study 11974451 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine-and-canine retainer
Number of subjects: 103
Study 11974451 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0195" canine-to-canine retainer
Number of subjects: 103
Study 11974451 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0215" canine-to-canine retainer
Number of subjects: 103
Study 11974451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry field bonding
Number of subjects: 103
Study 11974451 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatively dry field bonding
Number of subjects: 103
Study 11974451 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliosit composite
Number of subjects: 103
Study 11974451 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise composite
Number of subjects: 103
Study 11974451 — intervention group
Group type: EXPERIMENTAL
Intervention: All retainer types
Number of subjects: 103
Study 11974451 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine-and-canine retainers
Number of subjects: 103
Study 10438343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zanamivir (600 mg 2x/day for 5 days)
Number of subjects: 15
Study 10438343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7782954 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care for 4 hours a day, 6 days a week, for 3 weeks
Number of subjects: 8
Study 7782954 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Number of subjects: 8
Study 7782954 — intervention group
Group type: COMPARATOR
Intervention: Incubator care
Number of subjects: 8
Study 1981880 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced glutathione supplementation
Number of subjects: 0
Study 7006273 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol
Number of subjects: 13
Study 7006273 — intervention group
Group type: EXPERIMENTAL
Intervention: Norephedrine in combination with oestradiol
Number of subjects: 13
Study 7006273 — intervention group
Group type: COMPARATOR
Intervention: Norephedrine alone
Number of subjects: 13
Study 30988147 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lactam combination therapy (DBL)
Number of subjects: 2771
Study 30988147 — intervention group
Group type: COMPARATOR
Intervention: -lactam plus aminoglycoside combinations (BLAG)
Number of subjects: 2771
Study 29262823 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (interactive mobile phone quiz with phone credit rewards for correct answers)
Number of subjects: 0
Study 25358636 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic training alone (Group A)
Number of subjects: 15
Study 25358636 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic training with Botulinum toxin neurolysis (Group B)
Number of subjects: 15
Study 25358636 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 15
Study 23503651 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor oral hygiene (brushing teeth less than daily)
Number of subjects: 922
Study 23503651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth loss and DMFT score
Number of subjects: 922
Study 21679925 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic internet cognitive behavioral therapy (iCBT) program consisting of online educational lessons, homework assignments, weekly contact from a clinical psychologist, access to an online forum, and automated emails.
Number of subjects: 77
Study 21679925 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control group
Number of subjects: 77
Study 19139033 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise (three times/week) during the second and third trimester
Number of subjects: 160
Study 19139033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 160
Study 16404361 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg m(‐2) (day 1) (arm A)
Number of subjects: 44
Study 16404361 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg m(‐2) (day 8) and gemcitabine 1250 mg m(‐2) (days 1,8) (arm B)
Number of subjects: 44
Study 16404361 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 25 mg m(‐2) and gemcitabine 800 mg m(‐2) (both given weekly (days 1,8,15)) (arm C)
Number of subjects: 44
Study 16404361 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin AUC 7 followed by docetaxel-based therapy
Number of subjects: 44
Study 16404361 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-containing arms (arm B and arm C)
Number of subjects: 44
Study 15042003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free fetal DNA (cffDNA) measured before and after preeclampsia
Number of subjects: 120
Study 15042003 — intervention group
Group type: COMPARATOR
Intervention: Cell-free fetal DNA (cffDNA) measured before preeclampsia
Number of subjects: 120
Study 15042003 — intervention group
Group type: COMPARATOR
Intervention: Cell-free fetal DNA (cffDNA) measured within 3 weeks before preeclampsia
Number of subjects: 120
Study 15042003 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) serum concentrations
Number of subjects: 120
Study 10539396 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 633
Study 10539396 — intervention group
Group type: COMPARATOR
Intervention: Usual care without riluzole (Placebo)
Number of subjects: 633
Study 7793191 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 45
Study 7793191 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 45
Study 7793191 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Atracurium and Vecuronium (cAV)
Number of subjects: 45
Study 2111252 — intervention group
Group type: EXPERIMENTAL
Intervention: AA-861
Number of subjects: 0
Study 2111252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7238995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 46
Study 7238995 — intervention group
Group type: COMPARATOR
Intervention: Acenocoumarol
Number of subjects: 46
Study 31508730 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (2 hours)
Number of subjects: 14
Study 31508730 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study 28459941 — intervention group
Group type: EXPERIMENTAL
Intervention: iddEPC regimen (E 150 mg/m2, P 225 mg/m2, C 2500 mg/m2, reduced to 2000 mg/m2 after 1200 patients) q2w i.v.
Number of subjects: 2994
Study 28459941 — intervention group
Group type: COMPARATOR
Intervention: ddEC-PwX regimen (E 112.5 mg/m2 + C 600 mg/m2 i.v. q2w for 4 cycles, followed by Pw 67.5 mg/m2 i.v. q8d for 10 weeks + X 2000 mg/m2 p.o. days 1-14, q22 for 4 cycles)
Number of subjects: 2994
Study 24355670 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Challenge (multimodal e-mail, web, and mobile-based intervention)
Number of subjects: 1503
Study 24355670 — intervention group
Group type: COMPARATOR
Intervention: Traditional weekly health newsletter (control)
Number of subjects: 1503
Study 21880070 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde arterial flush (RGAF)
Number of subjects: 0
Study 21880070 — intervention group
Group type: COMPARATOR
Intervention: Non-RGAF (portal flush only)
Number of subjects: 0
Study 20518171 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) combined with auricular acupoint sticking (AAS), treated once each day for 15 days, with 3 courses of treatment evaluated after 45 days.
Number of subjects: 250
Study 20518171 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin Acetate (DA) and Meclofenoxate, treated for 2 months.
Number of subjects: 250
Study 17335683 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy
Number of subjects: 0
Study 17335683 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment algorithms based on published data and clinical experience
Number of subjects: 0
Study 17335683 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical research protocols
Number of subjects: 0
Study 15290001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg ethanol
Number of subjects: 11
Study 15290001 — intervention group
Group type: COMPARATOR
Intervention: juice (placebo)
Number of subjects: 11
Study 12403892 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-PTCA group (37 lesions with FFR >= 0.94 after PTCA)
Number of subjects: 155
Study 12403892 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-stent group (40 lesions with FFR < 0.94)
Number of subjects: 155
Study 12403892 — intervention group
Group type: COMPARATOR
Intervention: Control group (stent-only group, 78 lesions)
Number of subjects: 155
Study 12403892 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided patients (combined FFR-PTCA and FFR-stent)
Number of subjects: 155
Study 12403892 — intervention group
Group type: COMPARATOR
Intervention: Control group (stent-only group)
Number of subjects: 155
Study 12403892 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided patients
Number of subjects: 155
Study 12403892 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study 12403892 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided patients and control group
Number of subjects: 155
Study 9919645 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal inservice training program for foster parents
Number of subjects: 0
Study 9919645 — intervention group
Group type: EXPERIMENTAL
Intervention: Future foster parent training efforts
Number of subjects: 0
Study 7585311 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago photoscreener
Number of subjects: 1245
Study 7585311 — intervention group
Group type: COMPARATOR
Intervention: Manual technique
Number of subjects: 1245
Study 2105673 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg naltrexone
Number of subjects: 45
Study 2105673 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg naltrexone
Number of subjects: 45
Study 2105673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 7262174 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial capsule containing 50 mg of ketoprofen
Number of subjects: 12
Study 7262174 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple capsule containing 50 mg of ketoprofen
Number of subjects: 12
Study 7262174 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial capsule taken 6 hourly for thirteen doses
Number of subjects: 12
Study 7262174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen solution
Number of subjects: 12
Study 7262174 — intervention group
Group type: COMPARATOR
Intervention: Commercial capsule
Number of subjects: 12
Study 7262174 — intervention group
Group type: COMPARATOR
Intervention: Simple capsule
Number of subjects: 12
Study 30823946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound debridement technique
Number of subjects: 80
Study 30823946 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical debridement
Number of subjects: 80
Study 28041747 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fat graft
Number of subjects: 8
Study 28041747 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 8
Study 27556313 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 50
Study 27556313 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine management)
Number of subjects: 50
Study 25109244 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid nanoemulsion (BF-200 ALA)
Number of subjects: 13
Study 25109244 — intervention group
Group type: COMPARATOR
Intervention: methyl-5-aminolaevulinate (MAL)
Number of subjects: 13
Study 25109244 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-200 ALA
Number of subjects: 13
Study 25109244 — intervention group
Group type: COMPARATOR
Intervention: MAL
Number of subjects: 13
Study 25109244 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-200 ALA and MAL
Number of subjects: 13
Study 23063820 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 8
Study 23063820 — intervention group
Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 8
Study 19652072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/d (AM dosing)
Number of subjects: 107
Study 19652072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/d (PM dosing)
Number of subjects: 107
Study 19652072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/d
Number of subjects: 107
Study 17280919 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagine-patient perspective-taking
Number of subjects: 126
Study 17280919 — intervention group
Group type: COMPARATOR
Intervention: Imagine-self perspective-taking
Number of subjects: 126
Study 17280919 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 126
Study 17144773 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 15286420 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based education program on heart function, nutrition, and exercise for healthy heart and living tobacco free, presented for 2 hours per week over 8 weeks.
Number of subjects: 1128
Study 15286420 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 1128
Study 10771234 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐piece silicone multifocal IOL
Number of subjects: 20
Study 10771234 — intervention group
Group type: COMPARATOR
Intervention: 3‐piece acrylic IOL
Number of subjects: 20
Study 8653998 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (2 or 10 MU/m2/day SQ for 3 days) before etoposide
Number of subjects: 29
Study 8653998 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (2 or 10 MU/m2/day SQ for 3 days) concurrent with etoposide
Number of subjects: 29
Study 8653998 — intervention group
Group type: COMPARATOR
Intervention: Etoposide (75, 100, or 125 mg/m2/day)
Number of subjects: 29
Study 1735659 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded compression support hose
Number of subjects: 56
Study 1735659 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study 6299093 — intervention group
Group type: EXPERIMENTAL
Intervention: m-AMSA 120 mg/m2 intravenously every 3 weeks
Number of subjects: 89
Study 6299093 — intervention group
Group type: COMPARATOR
Intervention: neocarzinostatin 2.0 mg/m2 intravenously daily X 5 every 4 weeks
Number of subjects: 89
Study 30829505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 85
Study 30829505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy integrated with motivational interviewing
Number of subjects: 85
Study 27819755 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSD (novel penile circumcision suturing device)
Number of subjects: 124
Study 27819755 — intervention group
Group type: COMPARATOR
Intervention: SR (Shang ring)
Number of subjects: 124
Study 26905786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho-k lenses
Number of subjects: 78
Study 26905786 — intervention group
Group type: COMPARATOR
Intervention: Single-vision spectacles (control)
Number of subjects: 78
Study 25488084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum extractor
Number of subjects: 228
Study 25488084 — intervention group
Group type: COMPARATOR
Intervention: Forceps
Number of subjects: 228
Study 22338102 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based lifestyle intervention program (six sessions)
Number of subjects: 307
Study 22338102 — intervention group
Group type: COMPARATOR
Intervention: Wait control group
Number of subjects: 307
Study 19237657 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 20506
Study 17171458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral day treatment plus housing contingent on drug abstinence
Number of subjects: 138
Study 17171458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral day treatment plus housing not contingent on abstinence
Number of subjects: 138
Study 17171458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral day treatment plus no housing
Number of subjects: 138
Study 15080765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine solution 32 mg
Number of subjects: 20
Study 15080765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine tablet 16 mg
Number of subjects: 20
Study 15080765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine/naloxone tablet 16/4 mg
Number of subjects: 20
Study 15080765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine solution (all doses)
Number of subjects: 20
Study 15080765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine 16 mg tablet with naloxone
Number of subjects: 20
Study 11136142 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (2 mg/kg)
Number of subjects: 30
Study 11136142 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (2 mg/kg)
Number of subjects: 30
Study 9685762 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 percent sodium fluoride and 0.12 percent chlorhexidine rinses, daily from the end of the sixth month of pregnancy until delivery
Number of subjects: 0
Study 7988301 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg M1 intravenously
Number of subjects: 8
Study 7988301 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg M2 intravenously
Number of subjects: 8
Study 7988301 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg glibenclamide (Gb) intravenously
Number of subjects: 8
Study 7988301 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg glibenclamide (Gb) orally
Number of subjects: 8
Study 7988301 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously
Number of subjects: 8
Study 3058290 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (mean daily dose 3.34 mg)
Number of subjects: 52
Study 3058290 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (mean daily dose 192 mg)
Number of subjects: 52
Study 31693069 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-the-trainer condition
Number of subjects: 184
Study 31693069 — intervention group
Group type: COMPARATOR
Intervention: Expert condition
Number of subjects: 184
Study 31693069 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Train-the-trainer and Expert conditions
Number of subjects: 184
Study 30908711 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepaticogastrostomy (HGS)
Number of subjects: 47
Study 30908711 — intervention group
Group type: COMPARATOR
Intervention: Choledochoduodenostomy (CDS)
Number of subjects: 47
Study 29174961 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (0.4 mg kg−1)
Number of subjects: 20
Study 29174961 — intervention group
Group type: COMPARATOR
Intervention: Methadone (0.3 mg kg−1)
Number of subjects: 20
Study 25555532 — intervention group
Group type: EXPERIMENTAL
Intervention: WF‐LASIK
Number of subjects: 40
Study 25555532 — intervention group
Group type: COMPARATOR
Intervention: WF‐PRK
Number of subjects: 40
Study 25555532 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 23841572 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol esters (staest) - 3.0 g of plant stanols/d
Number of subjects: 92
Study 23841572 — intervention group
Group type: COMPARATOR
Intervention: Control group - rapeseed oil‐based spread without staest
Number of subjects: 92
Study 23841572 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol esters (staest)
Number of subjects: 92
Study 23841572 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92